Andfjord Salmon has entered into a commercial partnership with Scottish fish health analytics company WellFish Tech.
Under the agreement, WellFish Tech will deploy its WellFish Predict monitoring programme across active fish cohorts at Andfjord Salmon’s land-based salmon facility at Kvalnes, Norway.
The programme combines blood biomarker analysis with predictive models covering mortality risk and gill health, providing biological data intended to support production decisions alongside existing environmental and operational monitoring.
Andfjord Salmon operates a land-based flow-through facility using deep Arctic seawater and has previously reported survival rates above 99%.
“We have always believed that good outcomes for fish health are inseparable from good outcomes for the business, says Martin Rasmussen, CEO, Andfjord Salmon. “Our survival and growth data demonstrates what is possible when you give salmon the right environment – but we want to go further. Blood biochemistry gives us a direct window into the physiological state of our fish that no environmental sensor or behavioural observation can provide. We want the decisions we make at Kvalnes to be grounded in the most precise and robust data available, and this partnership gives us that.”
